{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-002126","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.201273+00:00","generated_at":"2026-06-19T07:06:53.350407+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AbCellera FY2022 revenue $485M, net income $158.5M; 23 new partnered programs started","bullets":["Total revenue $485.4M (up 29% YoY); net income $158.5M ($0.50 diluted EPS) vs $153.5M ($0.48 diluted) in 2021.","Royalties from COVID antibodies bamlanivimab/bebtelovimab were $443M; EUA for bebtelovimab suspended in Q4.","Partnership business: 23 new program starts, cumulative 101; 174 programs under contract with 40 partners.","Q4 net loss $29.9M; cash and marketable securities $886.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-002126","json":"https://secwatch.observer/filing/0001564590-23-002126.json","markdown":"https://secwatch.observer/filing/0001564590-23-002126.md","text":"https://secwatch.observer/filing/0001564590-23-002126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/0001564590-23-002126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/abcl-8k_20230221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:06:53.350407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdb779054b7c3db29f00d22bc789416eda3e5aba","claim":"AbCellera Biologics Inc. reported the year ended December 31, 2022 results: revenue $485.4 million in total revenue, net income $158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis, EPS $0.56 per share on a basic and $0.50 on a diluted basis.","evidence_excerpt":"as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- abcl-ex991_43.htm Exhibit 99.1 NEWS RELEASE AbCellera Reports Full Year 2022 Business Results 02/21/2023 • Total revenue of $485 million, compared to $375 million in FY 2021 • Total cumulative partnered program starts of 101, with 23 new starts in the year • Net earnings of $0.56 per share on a basic and $0.50 on","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/0001564590-23-002126-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$485.4 million in total revenue"},{"label":"Net income","value":"$158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis"},{"label":"EPS","value":"$0.56 per share on a basic and $0.50 on a diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}